Telomeres and Telomerase: Potential Targets for Platinum Complexes

Metal Complex-DNA Interactions

Volumn , Issue , 2009, Pages 209-234

  Ourliac Garnier, Isabelle ^a   Charif, Razan ^b   Bombard, Sophie ^b  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

G Quadruplex structures and small molecules; Interaction of cisplatin and related platinum complexes with telomeric DNA duplexes; Interactions of platinum complexes with telomerase; Telomerase role in cellular resistance to apoptosis; Telomere structure; Telomeres and telomerase; Telomeric DNA tandemly repeated G rich sequences of DNA

Indexed keywords

EID: 77953110015     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444312089.ch7     Document Type: Chapter

References (169)

1. Blackburn, E.H.; Telomere states and cell fates; Nature, 2000, 408(6808), 53-56.
2. Karlseder, J.; Smogorzewska, A.; de Lange, T.; Senescence induced by altered telomere state, not telomere loss; Science, 2002, 295(5564), 2446-2449.
3. Takai, H.; Smogorzewska, A.; de Lange, T.; DNA damage foci at dysfunctional telomeres; Curr. Biol., 2003, 13(17), 1549-1556.
4. de Lange, T.; Telomere-related genome instability in cancer;Cold Spring Harbour Symposium; Quant. Biol., 2005, 70, 197-204.
5. Londono-Vallejo, J.A.; Telomere instability and cancer; Biochimie, 2008, 90(1), 73-82.
6. de Lange, T.; Protection of mammalian telomeres; Oncogene, 2002, 21(4), 532-540.
7. Watson, J.; Origin of concatemeric T7 DNA; Nat. New Biol., 1972, 239, 197-201.
8. Olovnikov, A.M.; A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon; J. Theor. Biol., 1973, 41(1), 181-190.
9. Gilson, E.; Geli, V.; How telomeres are replicated; Nat. Rev. Mol. Cell Biol., 2007, 8(10), 825-838.
10. Verdun, R.E.; Karlseder, J.; Replication and protection of telomeres; Nature, 2007, 447(7147), 924-931.
11. Cimino-Reale, G.; Pascale, E.; Alvino, E.; Starace, G.; D'Ambrosio, E.; Long telomeric C-rich 5'-tails in human replicating cells; J. Biol. Chem., 2003, 278(4), 2136-2140.
12. Sfeir, A.J.; Chai, W.; Shay, J.W.; Wright, W.E.; Telomere-end processing the terminal nucleotides of human chromosomes; Mol. Cell., 2005, 18(1), 131-138.
13. Lenain, C.; Bauwens, S.; Amiard, S.; Brunori, M.; Giraud-Panis, M.J.; Gilson, E.; The Apollo 5' exonuclease functions together with TRF2 to protect telomeres from DNA repair; Curr. Biol, 2006, 16(13), 1303-1310.
14. Shay, J.W.; Wright, W.E.; Hayflick, his limit, and cellular ageing; Nat. Rev. Mol. Cell Biol., 2000, 1(1), 72-76.
15. Wright, W.E.; Shay, J.W.; Cellular senescence as a tumor-protection mechanism: the essential role of counting; Curr. Opin. Genet. Dev., 2001, 11(1), 98-103.
16. Shay, J.W.; Wright, W.E.; Hallmarks of telomeres in ageing research; J. Pathol., 2007, 211(2), 114-123.
17. Liu, D.; O'Connor, M.S.; Qin, J.; Songyang, Z.; Telosome, a mammalian telomere-associated complex formed by multiple telomeric proteins; J. Biol. Chem., 2004, 279(49), 51338-51342.
18. de Lange, T.; Shelterin: the protein complex that shapes and safeguards human telomeres; Genes Dev, 2005, 19(18), 2100-2110.
19. Chong, L.; van Steensel, B.; Broccoli, D.; Erdjument Bromage, H.; Hanish, J.; Tempst, P. et al.; A human telomeric protein; Science, 1995, 270(5242), 1663-1667.
20. Bilaud, T.; Brun, C.; Ancelin, K.; Koering, C.E.; Laroche, T.; Gilson, E.; Telomeric localization of TRF2, a novel human telobox protein; Nat. Genet., 1997, 17(2), 236-239.
21. Broccoli, D.; Smogorzewska, A.; Chong, L.; de Lange, T.; Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2; Nat. Genet., 1997, 17(2), 231-235.
22. Baumann, P.; Cech, T.R.; Pot1, the putative telomere end-binding protein in fission yeast and humans; Science, 2001, 292(5519), 1171-1175.
23. O'Connor, M.S.; Safari, A.; Xin, H.; Liu, D.; Songyang, Z.; A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly; Proc. Natl. Acad. Sci. USA, 2006, 103(32), 11874-11879.
24. Smogorzewska, A.; de Lange, T.; Regulation of telomerase by telomeric proteins; Annu. Rev. Biochem., 2004, 73, 177-208.
25. Griffith, J.D.; Comeau, L.; Rosenfield, S.; Stansel, R.M.; Bianchi, A.; Moss, H. et al.; Mammalian telomeres end in a large duplex loop [see comments]; Cell, 1999, 97(4), 503-514.
26. de Lange, T.; T-loops and the origin of telomeres; Nat. Rev. Mol. Cell. Biol., 2004, 5(4), 323-329.
27. van Steensel, B.; Smogorzewska, A.; de Lange, T.; TRF2 protects human telomeres from end-to-end fusions; Cell, 1998, 92(3), 401-413.
28. Denchi, E.L.; de Lange, T.; Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1; Nature, 2007, 448(7157), 1068-1071.
29. Celli, G.B.; Denchi, E.L.; de Lange, T.; Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination; Nat. Cell Biol., 2006, 8(8), 885-890.
30. Biroccio, A.; Gabellini, C.; Amodei, S.; Benassi, B.; Del Bufalo, D.; Elli, R. et al., Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells; Mol. Pharmacol., 2003, 63(3), 632-638.
31. Nakanishi, K.; Kawai, T.; Kumaki, F.; Hiroi, S.; Mukai, M.; Ikeda, E. et al.; Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung; Clin. Cancer Res., 2003, 9(3), 1105-1111.
32. Gu, J.; Spitz, M.R.; Zhao, H.; Lin, J.; Grossman, H.B.; Dinney, C.P. et al.; Roles of tumor suppressor and telomere maintenance genes in cancer and aging-an epidemiological study; Carcinogenesis, 2005, 26(10), 1741-1747.
33. Biroccio, A.; Rizzo, A.; Elli, R.; Koering, C.E.; Belleville, A.; Benassi, B. et al.; TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells; Eur. J. Cancer, 2006, 42(12), 1881-1888.
34. Colgin, L.M.; Baran, K.; Baumann, P.; Cech, T.R.; Reddel, R.R.; Human POT1 facilitates telomere elongation by telomerase; Curr. Biol., 2003, 13(11), 942-946.
35. Hockemeyer, D.; Palm, W.; Else, T.; Daniels, J.P; Takai, K.K.; Ye, J.Z. et al.; Telomere protection by mammalian Pot1 requires interaction with Tpp1; Nat. Struct. Mol. Biol., 2007, 14(8), 754-761.
36. Etheridge, K.T.; Compton, S.A.; Barrientos, K.S.; Ozgur, S.; Griffith, J.D.; Counter, C.M.; Tethering telomeric double-and single-stranded DNA binding proteins inhibits telomere elongation; J. Biol. Chem., 2008, 283(11), 6935-6941.
37. Wang, F.; Podell, E.R.; Zaug, A.J.; Yang, Y.; Baciu, P.; Cech, T.R. et al.; The POT1-TPP1 telomere complex is a telomerase processivity factor; Nature, 2007, 445(7127), 506-510.
38. Xin, H.; Liu, D.; Wan, M.; Safari, A.; Kim, H.; Sun, W. et al.; TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase; Nature, 2007, 445(7127), 559-562.
39. Blasco, M.A.; Telomeres and human disease: ageing, cancer and beyond; Nat. Rev. Genet., 2005, 6(8), 611-622.
40. Hockemeyer, D.; Sfeir, A.J.; Shay, J.W.; Wright, W.E.; de Lange, T.; POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end; EMBO J., 2005, 24(14), 2667-2678.
41. Celli, G.B.; de Lange, T.; DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion; Nat. Cell Biol., 2005, 7(7), 712-718.
42. Zhu, X.D.; Niedernhofer, L.; Kuster, B.; Mann, M.; Hoeijmakers, J.H.; de Lange, T.; ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes; Mol. Cell, 2003, 12(6), 1489-1498.
43. Wu, L.; Multani, A.S.; He, H.; Cosme-Blanco, W.; Deng, Y.; Deng, J.M. et al.; Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres; Cell, 2006, 126(1), 49-62.
44. He, H.; Multani, A.S.; Cosme-Blanco, W.; Tahara, H.; Ma, J.; Pathak, S. et al.; POT1b protects telomeres from end-t o-end chromosomal fusions and aberrant homologous recombination; EMBO J., 2006, 25(21), 5180-5190.
45. Greider, C.W.; Blackburn, E.H.; Identification of a specific telomere terminal transferase activity in Tetrahymena extracts; Cell, 1985, 43(2 Pt 1), 405-413.
46. Greider, C.W.; Telomerase activity, cell proliferation, and cancer; Proc. Natl. Acad. Sci. USA, 1998, 95(1), 90-92.
47. Broccoli, D.; Young, J.W.; de Lange, T.; Telomerase activity in normal and malignant hematopoietic cells; Proc. Natl. Acad. Sci. USA, 1995, 92(20), 9082-9086.
48. Masutomi, K.; Yu, E.Y.; Khurts, S.; Ben-Porath, I.; Currier, J.L.; Metz, G.B. et al.; Telomerase maintains telomere structure in normal human cells; Cell, 2003, 114(2), 241-253.
49. Morin, G.B., The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats;Cell, 1989, 59(3), 521-529.
50. Stewart, S.A.; Weinberg, R.A.; Telomeres: cancer to human aging; Annu. Rev. Cell Dev. Biol., 2006, 22, 531-557.
51. Bodnar, A.G.; Ouellette, M.; Frolkis, M.; Holt, S.E.; Chiu, C.P; Morin, G.B. et al.; Extension of life-span by introduction of telomerase into normal human cells [see comments]; Science, 1998, 279(5349), 349-352.
52. Hanahan, D.; Weinberg, R.A.; The hallmarks of cancer; Cell, 2000, 100(1), 57-70.
53. Mergny, J.L.; Riou, J.F.; Mailliet, P.; Teulade-Fichou, M.P; Gilson, E.; Natural and pharmacological regulation of telomerase; Nucleic Acids Res., 2002, 30(4), 839-865.
54. Lingner, J.; Hughes, T.R.; Shevchenko, A.; Mann, M.; Lundblad, V.; Cech, T.R.; Reverse transcriptase motifs in the catalytic subunit of telomerase [see comments]; Science, 1997, 276(5312), 561-567.
55. Chen, J.L.; Blasco, M.A.; Greider, C.W.; Secondary structure of vertebrate telomerase RNA; Cell, 2000, 100(5), 503-514.
56. Chen, J.L.; Greider, C.W.; Determinants in mammalian telomerase RNA that mediate enzyme processivity and cross-species incompatibility; EMBO J., 2003, 22(2), 304-314.
57. Cohen, S.B.; Graham, M.E.; Lovrecz, G.O.; Bache, N.; Robinson, P.J.; Reddel, R.R.; Protein composition of catalytically active human telomerase from immortal cells; Science, 2007, 315(5820), 1850-1853.
58. Mergny, J.L.; Lacroix, L.; Riou, J.F.; Telomerase: a dimeric menage a trois; Chembiochem., 2007, 8(13), 1483-1485.
59. Autexier, C.; Lue, N.F.; The structure and function of telomerase reverse transcriptase; Annu. Rev. Biochem., 2006, 75, 493-517.
60. Shay, J.W.; Wright, W.E.; Telomerase therapeutics for cancer: challenges and new directions; Nat. Rev. Drug Discov., 2006, 5(7), 577-584.
61. Olaussen, K.A.; Dubrana, K.; Domont, J.; Spano, J.P.; Sabatier, L., Soria, J.C.; Telomeres and telomerase as targets for anticancer drug development; Crit. Rev. Oncol. Hematol., 2006, 57(3), 191-214.
62. Pendino, F.; Tarkanyi, I.; Dudognon, C.; Hillion, J.; Lanotte, M.; Aradi, J. et al.; Telomeres and telomerase: Pharmacological targets for new anticancer strategies?; Curr. Cancer Drug Targets, 2006, 6(2), 147-180.
63. Kelland, L.; Targeting the limitless replicative potential of cancer: the telomerase/tel-omere pathway; Clin. Cancer Res., 2007, 13(17), 4960-4963.
64. Davis, J.T.; G-quartets 40 years later: from 5'-GMP to molecular biology and supramo-lecular chemistry; Angew. Chem. Int. Ed. Engl., 2004, 43(6), 668-698.
65. Burge, S.; Parkinson, G.N.; Hazel, P.; Todd, A.K.; Neidle, S.; Quadruplex DNA: sequence, topology and structure; Nucleic Acids Res., 2006, 34(19), 5402-5415.
66. Schaffitzel, C.; Berger, I.; Postberg, J.; Hanes, J.; Lipps, H.J.; Pluckthun, A.; In vitro generated antibodies specific for telomeric guanine-quadruplex DNA react with Stylonychia lemnae macronuclei; Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8572-8577.
67. Granotier, C.; Pennarun, G.; Riou, L.; Hoffschir, F.; Gauthier, L.R.; De Cian, A. et al.; Preferential binding of a G-quadruplex ligand to human chromosome ends; Nucleic Acids Res., 2005, 33(13), 4182-4190.
68. Paeschke, K.; Simonsson, T.; Postberg, J.; Rhodes, D.; Lipps, H.J.; Telomere end-binding proteins control the formation of G-quadruplex DNA structures in vivo; Nat. Struct. Mol. Biol., 2005, 12(10), 847-854.
69. Opresko, P.L.; Mason, P.A.; Podell, E.R.; Lei, M.; Hickson, I.D.; Cech, T.R. et al.; POT1 stimulates RecQ helicases WRN and BLM to unwind telomeric DNA substrates; J. Biol. Chem., 2005, 280(37), 32069-32080.
70. Huppert, J.L.; Balasubramanian, S.; Prevalence of quadruplexes in the human genome; Nucleic Acids Res., 2005, 33(9), 2908-2916.
71. Todd, A.K.; Johnston, M.; Neidle, S.; Highly prevalent putative quadruplex sequence motifs in human DNA; Nucleic Acids Res., 2005, 33(9), 2901-2907.
72. Huppert, J.L.; Balasubramanian, S.; G-quadruplexes in promoters throughout the human genome; Nucleic Acids Res., 2007, 35(2), 406-413.
73. Grand, C.L.; Han, H.; Munoz, R.M.; Weitman, S.; Von Hoff, D.D.; Hurley, L.H. et al.; The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo; Mol. CancerTher., 2002, 1(8), 565-573.
74. Parkinson, G.N.; Lee, M.P.; Neidle, S.; Crystal structure of parallel quadruplexes from human telomeric DNA; Nature, 2002, 417(6891), 876-880.
75. Wang, Y.; Patel, D. J.; Solution structure of the human telomeric repeat d[AG3(T2AG3)3] G-tetraplex; Structure, 1993, 1(4), 263-282.
76. Phan, A.T.; Kuryavyi, V.; Luu, K.N.; Patel, D.J.; Structure of two intramolecular G-quadruplexes formed by natural human telomere sequences in K+ solution; Nucleic Acids Res., 2007, 35(19), 6517-6525.
77. Luu, K.N.; Phan, A.T.; Kuryavyi, V.; Lacroix, L.; Patel, D.J.; Structure of human telomere in K+ solution: an intramolecular (3 + 1) G-quadruplex; J. Am. Chem. Soc., 2006, 128, 9963-9970.
78. Ourliac-Garnier, I.; Elizondo-Riojas, M.A.; Redon, S.; Farrell, N.P.; Bombard, S.; Crosslinks of quadruplex structures from human telomeric DNA by dinuclear platinum complexes show the flexibility of both structures; Biochemistry, 2005, 44(31), 10620-10634.
79. He, Y.J.; Neumann, R.D.; Panyutin, I.G.; Intramolecular quadruplex conformation of human telomeric DNA assessed with I-125-radioprobing; Nucleic Acids Res., 2004, 32(18), 5359-5367.
80. Ying, L.; Green, J.J.; Li, H.; Klenerman, D.; Balasubramanian, S.; Studies on the structure and dynamics of the human telomeric G quadruplex by single-molecule fluorescence resonance energy transfer; Proc. Natl. Acad. Sci. USA, 2003, 100(25), 14629-14634.
81. Ren, J.; Qu, X.; Trent, J.O.; Chaires, J.B.; Tiny telomere DNA; Nucleic Acids Res., 2002, 30(11), 2307-2315.
82. Zahler, A.M.; Williamson, J.R.; Cech, T.R.; Prescott, D.M.; Inhibition of telomerase by G-quartet DNA structures; Nature, 1991, 350(6320), 718-720.
83. Riou, J.F.; Guittat, L.; Mailliet, P.; Laoui, A.; Renou, E.; Petitgenet, O. et al.; Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands; Proc. Natl. Acad. Sci. SA, 2002, 99(5), 2672-2677.
84. De Cian, A.; Cristofari, G.; Reichenbach, P.; De Lemos, E.; Monchaud, D.; Teulade-Fichou, M.P. et al.; Reevaluation of telomerase inhibition by quadruplex ligands and their mechanisms of action; Proc. Natl. Acad. Sci. USA, 2007, 104(44), 17347-17352.
85. Gomez, D.; Paterski, R.; Lemarteleur, T.; Shin-Ya, K.; Mergny, J.L.; Riou, J.F.; Interaction of telomestatin with the telomeric single-strand overhang; J. Biol. Chem., 2004, 279(40), 41487-41494.
86. Gomez, D.; O'Donohue, M.F.; Wenner, T.; Douarre, C.; Macadre, J.; Koebel, P. et al.; The G-quadruplex ligand telomestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells; Cancer Res., 2006, 66(14), 6908-6912.
87. Gomez, D.; Wenner, T.; Brassart, B.; Douarre, C.; O'Donohue, M.F.; El Khoury, V. et al.; Telomestatin induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells; J. Biol. Chem., 2006, 2006-38721.
88. Tahara, H.; Shin-Ya, K.; Seimiya, H.; Yamada, H.; Tsuruo, T.; Ide, T.; G-quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells; Oncogene, 2006, 25(13), 1955-1966.
89. Salvati, E.; Leonetti, C.; Rizzo, A.; Scarsella, M.; Mottolese, M.; Galati, R. et al.; Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect; J. Clin. Invest., 2007, 117(11), 3236-3247.
90. Burger, A.M.; Dai, F.; Schultes, C.M.; Reszka, A.P.; Moore, M.J.; Double, J.A. et al.; The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function; Cancer Res., 2005, 65(4), 1489-1496.
91. Oganesian, L.; Bryan, T.M.; Physiological relevance of telomeric G-quadruplex formation: a potential drug target; Bioessays, 2007, 29(2), 155-165.
92. Maizels, N.; Dynamic roles for G4 DNA in the biology of eukaryotic cells; Nat. Struct. Mol. Biol., 2006, 13(12), 1055-1059.
93. De Cian, A.; Lacroix, L.; Douarre, C.; Temime-Smaali, N.; Trentesaux, C.; Riou, J.F. et al.; Targeting telomeres and telomerase; Biochimie, 2008, 90(1), 131-155.
94. Pisano, S.; Marchioni, E.; Galati, A.; Mechelli, R.; Savino, M.; Cacchione, S.; Telomeric nucleosomes are intrinsically mobile; J. Mol. Biol., 2007, 369(5), 1153-1162.
95. Phan, A.T.; Kuryavyi, V.; Patel, D.J.; DNA architecture: from G to Z; Curr. Opin. Struct. Biol., 2006, 16(3), 288-298.
96. Neidle, S.; Parkinson, G.; Telomere maintenance as a target for anticancer drug discovery; Nat. Rev. Drug Discov., 2002, 1(5), 383-393.
97. Monchaud, D.; Teulade-Fichou, M.P.; A hitchhiker's guide to G-quadruplex ligands; Org. Biomol. Chem., 2008, 6(4), 627-636.
98. Shin-ya, K.; Wierzba, K.; Matsuo, K.; Ohtani, T.; Yamada, Y.; Furihata, K. et al.; Telomes-tatin, a novel telomerase inhibitor from Streptomyces anulatus; J. Am. Chem. Soc., 2001, 123(6), 1262-1263.
99. Kim, M.Y.; Vankayalapati, H.; Shin-Ya, K.; Wierzba, K.; Hurley, L.H.; Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex; J. Am. Chem. Soc., 2002, 124(10), 2098-2099.
100. Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Okabe, S.; Ohyashiki, J.H. et al.; Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia; Oncogene, 2006, 25(42), 5719-5725.
101. Gavathiotis, E.; Heald, R.A.; Stevens, M.F.; Searle, M.S.; Recognition and stabilization of quadruplex DNA by a potent new telomerase inhibitor: NMR studies of the 2:1 complex of a pentacyclic methylacridinium cation with d(TTAGGGT); Angew. Chem. Int. Ed. Engl., 2001, 40(24), 4749-4751.
102. Gavathiotis, E.; Heald, R.A.; Stevens, M.F.; Searle, M.S.; Drug recognition and stabilisation of the parallel-stranded DNA quadruplex d(TTAGGGT)4 containing the human telomeric repeat; J. Mol. Biol., 2003, 334(1), 25-36.
103. Fedoroff, O.Y.; Salazar, M.; Han, H.; Chemeris, V.V.; Kerwin, S.M.; Hurley, L.H.; NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA; Biochemistry, 1998, 37(36), 12367-12374.
104. Haider, S.M.; Parkinson, G.N.; Neidle, S.; Structure of a G-quadruplex-ligand complex; J. Mol. Biol.; 2003, 326(1), 117-125.
105. Clark, G.R.; Pytel, P.D.; Squire, C.J.; Neidle, S.; Structure of the first parallel DNA quadruplex-drug complex; J. Am. Chem. Soc., 2003, 125(14), 4066-4067.
106. Cocco, M.J.; Hanakahi, L. A.; Huber, M.D.; Maizels, N.; Specific interactions of distamycin with G-quadruplex DNA; NucleicAcids Res., 2003, 31(11), 2944-2951.
107. Reed, J.E.; Arnal, A.A.; Neidle, S.; Vilar, R.; Stabilization of G-quadruplex DNA and inhibition of telomerase activity by square-planar nickel(II) complexes; J. Am. Chem. Soc, 2006, 128(18), 5992-5993.
108. Bertrand, H.; Monchaud, D.; De Cian, A.; Guillot, R.; Mergny, J.L.; Teulade-Fichou, M.P.; The importance of metal geometry in the recognition of G-quadruplex-DNA by metal-terpyridine complexes; Org. Biomol. Chem., 2007, 5(16), 2555-2559.
109. Reed, J.E.; Arnal, A.A.; Neidle, S.; Vilar, R.; Stabilization of G-quadruplex DNA and inhibition of telomerase activity by square-planar nickel(II) complexes; J. Am. Chem. Soc, 2006, 128(18), 5992-5993.
110. Dixon, I.M.; Lopez, F.; Tejera, A.M.; Esteve, J.P.; Blasco, M.A.; Pratviel, G. et al.; A G-quadruplex ligand with 10000-fold selectivity over duplex DNA; J. Am. Chem. Soc., 2007, 129(6), 1502-1503.
111. Evans, S.E.; Mendez, M.A.; Turner, K.B.; Keating, L.R.; Grimes, R.T.; Melchoir, S. et al.; End-stacking of copper cationic porphyrins on parallel-stranded guanine quadruplexes; J. Biol. Inorg. Chem., 2007, 12(8), 1235-1249.
112. Keating, L.R.; Szalai, V.A.; Parallel-stranded guanine quadruplex interactions with a copper cationic porphyrin; Biochemistry, 2004, 43(50), 15891-15900.
113. Maraval, A.; Franco, S.; Vialas, C.; Pratviel, G.; Blasco, M.A.; Meunier, B.; Porphyrin-aminoquinoline conjugates as telomerase inhibitors; Org. Biomol. Chem., 2003 1(6), 921-927.
114. Dixon, I.M.; Lopez, F.; Esteve, J.P.; Tejera, A.M.; Blasco, M.A.; Pratviel, G. et al.; Porphyrin derivatives for telomere binding and telomerase inhibition; Chembiochem., 2005, 6(1), 123-132.
115. Ren, L.; Zhang, A.; Huang, J.; Wang, P.; Weng, X.; Zhang, L. et al.; Quaternary ammonium zinc phthalocyanine: inhibiting telomerase by stabilizing G-quadruplexes and inducing G-quadruplex structure transition and formation; Chembiochem., 2007, 8(7), 775-780.
116. Zhang, L.; Huang, J.; Ren, L.; Bai, M.; Wu, L.; Zhai, B. et al.; Synthesis and evaluation of cationic phthalocyanine derivatives as potential inhibitors of telomerase; Bioorg. Med. Chem., 2008, 16(1), 303-312.
117. Rosenberg, B.; Van Camp, L.; Krigas, T.; Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode; Nature, 1965, 205(4972), 698-699.
118. Wang, D.; Lippard, S.J.; Cellular processing of platinum anticancer drugs; Nat. Rev. Drug Discov., 2005, 4(4), 307-320.
119. Jung, Y.; Lippard, S.J.; Direct cellular responses to platinum-induced DNA damage; Chem. Rev., 2007, 107(5), 1387-1407.
120. Jamieson, E.R.; Lippard, S.J.; Structure, recognition, and processing of cisplatin-DNA adducts; Chem. Rev., 1999, 99, 2467-2498.
121. Kelland, L.; The resurgence of platinum-based cancer chemotherapy; Nat. Rev. Cancer, 2007, 7(8), 573-584.
122. Kieltyka, R.; Fakhoury, J.; Moitessier, N.; Sleiman, H.F.; Platinum phenanthroimidazole complexes as G-quadruplex DNA selective binders; Chemistry, 2007, 14(4), 1145-1154.
123. Reed, J.E.; Neidle, S.; Vilar, R.; Stabilisation of human telomeric quadruplex DNA and inhibition of telomerase by a platinum-phenanthroline complex; Chem. Commun. (Camb.), 2007, (42), 4366-4368.
124. Redon, S.; Bombard, S.; Elizondo-Riojas, M.A.; Chottard, J.C.; Platination of the (T2G4)4 telomeric sequence: a structural and cross-linking study; Biochemistry, 2001, 40(29), 8463-8470.
125. Redon, S.; Bombard, S.; Elizondo-Riojas, M.A.; Chottard, J.C.; Platinum cross-linking of adenines and guanines on the quadruplex structures of the AG3(T2AG3)3 and (T2AG3)4 human telomere sequences in Na+ and K+ solutions; Nucleic Acids Res., 2003, 31, 1605-1613.
126. Ourliac Garnier, I.; Bombard, S.; GG sequence of DNA and the human telomeric sequence react with cis-diammine-diaquaplatinum at comparable rates; J. Inorg. Biochem., 2007, 101(3), 514-524.
127. Bertrand, H.; Bombard, S.; Monchaud, D.; Teulade-Fichou, M.P; A platinum-quinacridine hybrid as G-quadruplex ligand; J. Inorg. Biol. Chem., 2007, 12, 1003-1014.
128. Williamson, J.R.; Raghuraman, M.K.; Cech, T.R.; Monovalent cation-induced structure of telomeric DNA: the G-quartet model; Cell, 1989, 59(5), 871-880.
129. Henderson, E.R.; Moore, M.; Malcolm, B.A., Telomere G-strand structure and function analyzed by chemical protection, base analogue substitution, and utilization by telom-erase in vitro; Biochemistry, 1990, 29(3), 732-737.
130. Wang, Y.; Patel, D.J.; Solution structure of the Tetrahymena telomeric repeat d(T2G4)4 G-tetraplex; Structure, 1994, 2(12), 1141-1156.
131. Cuesta, J.; Read, M.A.; Neidle, S.; The design of G-quadruplex ligands as telomerase inhibitors; Mini Rev. Med. Chem., 2003, 3(1), 11-21.
132. Kasparkova, J.; Farrell, N.; Brabec, V.; Sequence specificity, conformation, and recognition by HMG1 protein major DNA interstrand cross-links of antitumor dinuclear platinum complexes; J. Biol. Chem., 2000, 275(21), 15789-15798.
133. Hounsou, C.; Guittat, L.; Monchaud, D.; Jourdan, M.; Saettel, N.; Mergny, J.L. et al.; G-quadruplex recognition by quinacridines: a SAR, NMR, and biological study; ChemMed-Chem, 2007, 2(5), 655-666.
134. Rao, L.; Bierbach, U.; Kinetically favored platination of adenine in the G-rich human telomeric repeat; J. Am. Chem. Soc., 2007, 129(51), 15764-15765.
135. Martin, R.B.; Platinum complexes: Hydrolysis and binding to N(7) and N(1) of purines. In: Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Lippert, B., Ed., Wiley-VCH, Zürick, 1999, 183-206.
136. Burstyn, J.N.; Heiger-Bernays, W. J.; Cohen, S.M.; Lippard, S.J.; Formation of cis-diammi nedichloroplatinum(II) 1, 2-intrastrand cross-links on DNA is flanking-sequence independent; Nucleic Acids Res., 2000, 28(21), 4237-4243.
137. Villa, R.; Folini, M.; Perego, P.; Supino, R.; Setti, E.; Daidone, M.G. et al.; Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents; Int. J. Oncol., 2000, 16(5), 995-1002.
138. Jeyapalan, J.C.; Saretzki, G.; Leake, A.; Tilby, M.J.; von Zglinicki, T.; Tumour-cell apop-tosis after cisplatin treatment is not telomere dependent; Int. J. Cancer, 2006, 118(11), 2727-2734.
139. Opresko, P.L.; Fan, J.; Danzy, S.; Wilson, D.M., 3rd; Bohr, V.A.; Oxidative damage in telomeric DNA disrupts recognition by TRF1 and TRF2; Nucleic Acids Res., 2005, 33(4), 1230-1239.
140. Ourliac-Garnier, I.; Poulet, A.; Amiard, S.; Gilson, E.; Giraud-Panis, M.; Bombard, S.; Platination of telomeric DNA by cisplatin disrupts recognition by TRF2 and TRF1; manuscript in preparation 2008.
141. Chen, J.L.; Blasco, M.A.; Greider, C.W.; Secondary structure of vertebrate telomerase RNA; Cell, 2000, 100(5), 503-514.
142. Norton, J.C.; Piatyszek, M.A.; Wright, W.E.; Shay, J.W.; Corey, D.R.; Inhibition of human telomerase activity by peptide nucleic acids; Nat. Biotechnol., 1996, 14(5), 615-619.
143. Keppler, B.R.; Jarstfer, M.B.; Inhibition of telomerase activity by preventing proper assemblage; Biochemistry, 2004, 43(2), 334-343.
144. Keppler, B.R.; Jarstfer, M.B.; A high-throughput assay for a human telomerase protein-human telomerase RNA interaction; Anal. Biochem., 2006, 353(1), 75-82.
145. Herbert, B.S.; Gellert, G.C.; Hochreiter, A.; Pongracz, K.; Wright, W.E; Zielinska, D. et al.; Lipid modification of GRN163, an N3'-& gt;P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition; Oncogene, 2005, 24(33), 5262-5268.
146. Gellert, G.C.; Dikmen, Z.G.; Wright, W.E.; Gryaznov, S.; Shay, J.W.; Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer; Breast Cancer Res. Treat., 2006, 96(1), 73-81.
147. Colangelo, D.; Osella, D.; Telomerase inhibition and cancer: might platinum based drugs have a future as anti-telomerase pharmacological approach?; Curr. Med. Chem., 2005, 12(26), 3091-3102.
148. Colangelo, D.; Ghiglia, A.L.; Viano, I.; Cavigiolio, G.; Osella, D.; Cis-[Pt(Cl)2(pyridine)(5-SO3H--soquinoline)] complex, a selective inhibitor of telomerase enzyme; Biometals, 2003, 16(4), 553-560.
149. Furuta, M.; Nozawa, K.; Takemura, M.; Izuta, S.; Murate, T.; Tsuchiya, M. et al.; A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line; Int. J. Cancer, 2003, 104(6), 709-715.
150. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.; West, M.D.; Ho, P.L. et al.; Specific association of human telomerase activity with immortal cells and cancer [see comments]; Science, 1994, 266(5193), 2011-2015.
151. Knox, R.J.; Friedlos, F.; Lydall, D.A.; Roberts, J.J.; Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1, 1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA; Cancer Res., 1986, 46(4 Pt 2), 1972-1979.
152. Ishibashi, T.; Lippard, S. J.; Telomere loss in cells treated with cisplatin; Proc. Natl. Acad. Sci. USA, 1998, 95(8), 4219-4223.
153. Zhang, R.G.; Zhang, R.P.; Wang, X.W.; Xie, H.; Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells; Cell Res., 2002, 12(1), 55-62.
154. Ishii, K.; Yang, W.L.; Cvijic, M.E.; Kikuchi, Y.; Nagata, I.; Chin, K.V.; Telomere shortening by cisplatin in yeast nucleotide excision repair mutant; Exp. Cell Res., 2000, 225, 95-101.
155. Brabec, V.; Kasparkova, J.; Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs; Drug Resist. Updat., 2005, 8(3), 131-146.
156. Sedletska, Y.; Giraud-Panis, M.J.; Malinge, J.M.; Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways; Curr, Med. Chem. Anticancer Agents, 2005, 5(3), 251-265.
157. Burger, A.M.; Double, J.A.; Newell, D.R.; Inhibition of telomerase activity by cisplatin in human testicular cancer cells; Eur. J. Cancer, 1997, 33(4), 638-644.
158. Raymond, E.; Sun, D.; Izbicka, E.; Mangold, G.; Silvas, E.; Windle, B. et al.; A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay; Br. J. Cancer, 1999, 80(9), 1332-1341.
159. Akiyama, M.; Horiguchi-Yamada, J.; Saito, S.; Hoshi, Y.; Yamada, O.; Mizoguchi, H. et al.; Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro; Eur. J. Cancer, 1999, 35(2), 309-315.
160. Akeshima, R.; Kigawa, J.; Takahashi, M.; Oishi, T.; Kanamori, Y.; Itamochi, H. et al.; Telomerase activity and p53-dependent apoptosis in ovarian cancer cells; Br. J. Cancer, 2001, 84(11), 1551-1555.
161. Ku, W.C.; Cheng, A.J.; Wang, T.C.; Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture; Biochem. Biophys. Res. Commun., 1997, 241(3), 730-736.
162. Spiropoulou, T.; Ferekidou, L.; Angelopoulou, K.; Stathopoulou, A.; Talieri, M.; Lianidou, E.S.; Effect of antineoplastic agents on the expression of human telomerase reverse transcriptase beta plus transcript in MCF-7 cells; Clin. Biochem., 2004, 37(4), 299-304.
163. Kondo, Y.; Kondo, S.; Tanaka, Y.; Haqqi, T.; Barna, B.P.; Cowell, J.K.; Inhibition of telom-erase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis; Oncogene, 1998, 16(17), 2243-2248.
164. Ward, R.J.; Autexier, C.; Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment; Mol. Pharmacol., 2005, 68(3), 779-786.
165. Folini, M.; De Marco, C.; Orlandi, L.; Daidone, M.G.; Zaffaroni, N.; Attenuation of tel-omerase activity does not increase sensitivity of human melanoma cells to anticancer agents; Eur. J. Cancer, 2000, 36(16), 2137-2145.
166. Chen, Z.; Koeneman, K.S.; Corey, D.R.; Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells; Cancer Res. 2003, 63(18), 5917-5925.
167. Buttitta, F.; Pellegrini, C.; Marchetti, A.; Gadducci, A.; Cosio, S.; Felicioni, L. et al.; Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma; J. Clin. Oncol., 2003, 21(7), 1320-1325.
168. Asai, A.; Kiyozuka, Y.; Yoshida, R.; Fujii, T.; Hioki, K.; Tsubura, A.; Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs; Anticancer Res., 1998, 18(3A), 1465-1472.
169. Lee, K.H.; Rudolph, K.L.; Ju, Y.J.; Greenberg, R.A.; Cannizzaro, L.; Chin, L. et al.; Telomere dysfunction alters the chemotherapeutic profile of transformed cells; Proc. Natl. Acad. Sci. USA, 2001, 98(6), 3381-3386.